Daiichi Sankyo

We track 2 ClinicalTrials.gov studies led by Daiichi Sankyo. The portfolio skews toward Phase 3 (1 trials).

2 clinical trials sponsored by Daiichi Sankyo.

Pipeline by Phase

PhaseTrialsDistribution
Phase 3 1
50%
Phase 2 1
50%

Trial Status Breakdown

Trials by Daiichi Sankyo

A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15)

NCT05950945 · RECRUITING · Phase 3

HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

NCT04619004 · ACTIVE NOT RECRUITING · Phase 2

Frequently Asked Questions

How many clinical trials does Daiichi Sankyo sponsor?

Daiichi Sankyo currently sponsors 2 clinical trials tracked on ReadTheTrial. These span Phase 3, Phase 2.

What conditions does Daiichi Sankyo research?

Daiichi Sankyo conducts research across multiple therapeutic areas. Browse the trial listings for details.

Is Daiichi Sankyo recruiting for clinical trials?

Yes, Daiichi Sankyo currently has 1 trial that are actively recruiting participants. Check individual trial pages for eligibility criteria and locations.

Explore More